INREBIC Market Summary

Key Factors Driving INREBIC Growth

1. Established efficacy in frontline and post-ruxolitinib myelofibrosis patients

INREBIC (fedratinib) is an oral, selective JAK2 inhibitor approved for adults with intermediate-2 or high-risk primary or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia). Its approval was supported by the Phase III JAKARTA trial, where approximately 37% of patients receiving fedratinib 400 mg achieved a ≥35% reduction in spleen volume at Week 24 compared with 1% in the placebo arm. The Phase II JAKARTA2 study further demonstrated clinically meaningful spleen and symptom responses in patients previously treated with ruxolitinib, providing an important treatment option after frontline JAK inhibitor failure. These robust efficacy data continue to support physician confidence and sustained adoption.

2. Significant unmet need following ruxolitinib failure

Myelofibrosis remains a rare disease with limited therapeutic options. More than 50% of patients discontinue ruxolitinib within 3–5 years because of disease progression, intolerance, or inadequate response, creating a sizeable second-line treatment population. INREBIC remains one of the few approved therapies specifically supported by prospective clinical data in this setting, making it an important option for hematologists managing patients with progressive disease.

3. Growing real-world evidence supporting clinical outcomes

Increasing real-world evidence is strengthening INREBIC's market position. A 2023 observational study using the Flatiron Health database reported that patients receiving fedratinib after ruxolitinib demonstrated improved survival compared with those receiving other post-ruxolitinib therapies. Median overall survival was not reached in the fedratinib cohort versus 17 months in comparator patients, while estimated 12-month survival was 71.6% versus 53.5%, respectively. Such evidence is likely to reinforce physician confidence and encourage broader utilization in routine clinical practice.

4. Broader treatable patient population through efficacy in thrombocytopenic patients

Additional analyses from the JAKARTA and JAKARTA2 trials demonstrated that fedratinib maintains comparable spleen and symptom response rates in patients with baseline platelet counts between 50 and <100 × 10⁹/L, a subgroup that is often difficult to treat. These findings expand physician confidence in using INREBIC across a broader spectrum of myelofibrosis patients while supporting treatment continuity in individuals with baseline thrombocytopenia.

5. Convenient oral administration and differentiated JAK2 selectivity

INREBIC is administered as a once-daily oral therapy, improving convenience compared with more complex treatment approaches. Its high selectivity for JAK2 provides effective control of splenomegaly and constitutional symptoms while offering a differentiated mechanism within the evolving JAK inhibitor landscape. As treatment sequencing becomes increasingly important in myelofibrosis management, INREBIC continues to occupy a well-defined role alongside other approved JAK inhibitors.

INREBIC Recent Developments

In April 2026, BMS Australia announced that the Pharmaceutical Benefits Scheme (PBS) listed INREBIC for MF (including JAK‑inhibitor–naïve and post‑ruxolitinib patients, and certain intermediate‑1 patients with severe, refractory symptoms). This is a key reimbursement milestone enabling broader patient access in Australia.

“INREBIC Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of INREBIC for approved indication like Myelofibrosis in the 7MM. A detailed picture of INREBIC’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the INREBIC for approved indications. The INREBIC market report provides insights about INREBIC’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current INREBIC performance, future market assessments inclusive of the INREBIC market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of INREBIC sales forecasts, along with factors driving its market.

INREBIC Drug Summary

INREBIC (Fedratinib) is an oral, selective inhibitor of Janus kinase 2 (JAK2) approved for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera and post-essential thrombocythemia myelofibrosis. INREBIC works by inhibiting constitutively activated JAK2 signaling, thereby reducing abnormal myeloproliferation, inflammatory cytokine production, splenomegaly, and disease-related symptoms such as fatigue, night sweats, and weight loss. Administered orally once daily, INREBIC demonstrated significant reductions in spleen volume and symptom burden in pivotal clinical trials, including patients previously treated with other JAK inhibitors. Common adverse events include gastrointestinal symptoms (nausea, vomiting, diarrhea), anemia, and thrombocytopenia, while treatment requires monitoring for thiamine deficiency due to the risk of Wernicke's encephalopathy. Initially approved by the U.S. FDA in 2019, INREBIC has become an important therapeutic option for patients with myelofibrosis, particularly those who are intolerant of or have an inadequate response to first-line JAK inhibitor therapy. The report provides INREBIC’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the INREBIC Market Report

The report provides insights into:

• A comprehensive product overview including the INREBIC MoA, description, dosage and administration, research and development activities in approved indication like Myelofibrosis.
• Elaborated details on INREBIC regulatory milestones and other development activities have been provided in INREBIC market report.
• The report also highlights INREBIC‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The INREBIC market report also covers the patents information, generic entry and impact on cost cut.
• The INREBIC market report contains current and forecasted INREBIC sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The INREBIC market report also features the SWOT analysis with analyst views for INREBIC in approved indications.

Methodology

The INREBIC market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INREBIC Analytical Perspective by DelveInsight

• In-depth INREBIC Market Assessment

This INREBIC sales market forecast report provides a detailed market assessment of INREBIC for approved indication like Myelofibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted INREBIC sales data uptil 2034.

• INREBIC Clinical Assessment

The INREBIC market report provides the clinical trials information of INREBIC for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

INREBIC Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

INREBIC Market Potential & Revenue Forecast

• Projected market size for the INREBIC and its key indications
• Estimated INREBIC sales potential (INREBIC peak sales forecasts)
• INREBIC Pricing strategies and reimbursement landscape

INREBIC Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• INREBIC Market positioning compared to existing treatments
• INREBIC Strengths & weaknesses relative to competitors

INREBIC Regulatory & Commercial Milestones

• INREBIC Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

INREBIC Clinical Differentiation

• INREBIC Efficacy & safety advantages over existing drugs
• INREBIC Unique selling points

INREBIC Market Report Highlights

• In the coming years, the INREBIC market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The INREBIC companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INREBIC’s dominance.
• Other emerging products for Myelofibrosis are expected to give tough market competition to INREBIC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INREBIC in approved indications.
• Analyse INREBIC cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted INREBIC sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of INREBIC in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of INREBIC? How strong is INREBIC’s clinical and commercial performance?
• What is INREBIC’s clinical trial status in each individual indications such as Myelofibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INREBIC Manufacturers?
• What are the key designations that have been granted to INREBIC for approved indications? How are they going to impact INREBIC’s penetration in various geographies?
• What is the current and forecasted INREBIC market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of INREBIC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to INREBIC for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is INREBIC? What is the duration of therapy and what are the geographical variations in cost per patient?